Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-ALL

This study tests CD5-targeted CAR-T cell therapy for people with relapsed or refractory CD5-positive T-cell acute lymphoblastic leukemia (T-ALL), a type of blood cancer. CAR-T therapy engineers the patient's own immune cells in a lab to target and destroy cancer cells marked with the CD5 protein. This is for patients whose cancer has come back or stopped responding to standard chemotherapy. **You may be eligible if...** - You have been diagnosed with CD5-positive T-ALL that has relapsed or not responded to prior treatment - Your cancer did not achieve complete remission after standard treatment, or it came back within 12 months - More than 90% of your leukemia cells carry the CD5 protein - Your heart, liver, and kidney function, as well as oxygen levels, meet minimum thresholds - You are physically functional enough for treatment (ECOG 0–2) - You are willing to use reliable contraception for 6 months after the final cell infusion **You may NOT be eligible if...** - You have a history of epilepsy or other central nervous system disorders - You have prolonged QT interval on an electrocardiogram or serious heart disease - You have active hepatitis B, C, or E infections - You have uncontrolled active infections - You have previously received any gene therapy - You received certain cancer treatments within the past few days or weeks Talk to your doctor to see if this trial is right for you.